Shilpa Grover1,2,3,4, Fay Kastrinos5,6, Ewout W Steyerberg7, E Francis Cook8, Akriti Dewanwala3, Lynn Anne Burbidge9, Richard J Wenstrup9, Sapna Syngal1,2,3. 1. Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA. 2. Harvard Medical School, Boston, MA. 3. Population Sciences Division, Dana-Farber Cancer Institute, Boston, MA. 4. Program in Cancer Outcomes Research Training, Massachusetts General Hospital, Boston, MA. 5. Columbia University Medical Center, New York, NY. 6. Herbert Irving Comprehensive Cancer Center, New York, NY. 7. Center for Medical Decision Making, Erasmus Medical Center, Rotterdam, Netherlands. 8. Harvard School of Public Health, Boston, MA. 9. Myriad Genetic Laboratories Inc., Salt Lake City, UT.
Abstract
CONTEXT: Patients with multiple colorectal adenomas may carry germline mutations in the APC or MUTYH genes. OBJECTIVES: To determine the prevalence of pathogenic APC and MUTYH mutations in patients with multiple colorectal adenomas who had undergone genetic testing and to compare the prevalence and clinical characteristics of APC and MUTYH mutation carriers. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study conducted among 8676 individuals who had undergone full gene sequencing and large rearrangement analysis of the APC gene and targeted sequence analysis for the 2 most common MUTYH mutations (Y179C and G396D) between 2004 and 2011. Individuals with either mutation underwent full MUTYH gene sequencing. APC and MUTYH mutation prevalence was evaluated by polyp burden; the clinical characteristics associated with a pathogenic mutation were evaluated using logistic regression analyses. MAIN OUTCOME MEASURE: Prevalence of pathogenic mutations in APC and MUTYH genes. RESULTS: Colorectal adenomas were reported in 7225 individuals; 1457 with classic polyposis (≥100 adenomas) and 3253 with attenuated polyposis (20-99 adenomas). The prevalence of pathogenic APC and biallelic MUTYH mutations was 95 of 119 (80% [95% CI, 71%-87%]) and 2 of 119 (2% [95% CI, 0.2%-6%]), respectively, among individuals with 1000 or more adenomas, 756 of 1338 (56% [95% CI, 54%-59%]) and 94 of 1338 (7% [95% CI, 6%-8%]) among those with 100 to 999 adenomas, 326 of 3253 (10% [95% CI, 9%-11%]) and 233 of 3253 (7% [95% CI, 6%-8%]) among those with 20 to 99 adenomas, and 50 of 970 (5% [95% CI, 4%-7%]) and 37 of 970 (4% [95% CI, 3%-5%]) among those with 10 to 19 adenomas. Adenoma count was strongly associated with a pathogenic mutation in multivariable analyses. CONCLUSIONS: Among patients with multiple colorectal adenomas, pathogenic APC and MUTYH mutation prevalence varied considerably by adenoma count, including within those with a classic polyposis phenotype. APC mutations predominated in patients with classic polyposis, whereas prevalence of APC and MUTYH mutations was similar in attenuated polyposis. These findings require external validation.
CONTEXT: Patients with multiple colorectal adenomas may carry germline mutations in the APC or MUTYH genes. OBJECTIVES: To determine the prevalence of pathogenic APC and MUTYH mutations in patients with multiple colorectal adenomas who had undergone genetic testing and to compare the prevalence and clinical characteristics of APC and MUTYH mutation carriers. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study conducted among 8676 individuals who had undergone full gene sequencing and large rearrangement analysis of the APC gene and targeted sequence analysis for the 2 most common MUTYH mutations (Y179C and G396D) between 2004 and 2011. Individuals with either mutation underwent full MUTYH gene sequencing. APC and MUTYH mutation prevalence was evaluated by polyp burden; the clinical characteristics associated with a pathogenic mutation were evaluated using logistic regression analyses. MAIN OUTCOME MEASURE: Prevalence of pathogenic mutations in APC and MUTYH genes. RESULTS:Colorectal adenomas were reported in 7225 individuals; 1457 with classic polyposis (≥100 adenomas) and 3253 with attenuated polyposis (20-99 adenomas). The prevalence of pathogenic APC and biallelic MUTYH mutations was 95 of 119 (80% [95% CI, 71%-87%]) and 2 of 119 (2% [95% CI, 0.2%-6%]), respectively, among individuals with 1000 or more adenomas, 756 of 1338 (56% [95% CI, 54%-59%]) and 94 of 1338 (7% [95% CI, 6%-8%]) among those with 100 to 999 adenomas, 326 of 3253 (10% [95% CI, 9%-11%]) and 233 of 3253 (7% [95% CI, 6%-8%]) among those with 20 to 99 adenomas, and 50 of 970 (5% [95% CI, 4%-7%]) and 37 of 970 (4% [95% CI, 3%-5%]) among those with 10 to 19 adenomas. Adenoma count was strongly associated with a pathogenic mutation in multivariable analyses. CONCLUSIONS: Among patients with multiple colorectal adenomas, pathogenic APC and MUTYH mutation prevalence varied considerably by adenoma count, including within those with a classic polyposis phenotype. APC mutations predominated in patients with classic polyposis, whereas prevalence of APC and MUTYH mutations was similar in attenuated polyposis. These findings require external validation.
Authors: P Van Duijvendijk; J F Slors; C W Taat; P Oosterveld; M A Sprangers; H Obertop; H F Vasen Journal: Br J Surg Date: 2000-05 Impact factor: 6.939
Authors: Nada Al-Tassan; Nikolas H Chmiel; Julie Maynard; Nick Fleming; Alison L Livingston; Geraint T Williams; Angela K Hodges; D Rhodri Davies; Sheila S David; Julian R Sampson; Jeremy P Cheadle Journal: Nat Genet Date: 2002-01-30 Impact factor: 38.330
Authors: Oliver M Sieber; Lara Lipton; Michael Crabtree; Karl Heinimann; Paulo Fidalgo; Robin K S Phillips; Marie-Luise Bisgaard; Torben F Orntoft; Lauri A Aaltonen; Shirley V Hodgson; Huw J W Thomas; Ian P M Tomlinson Journal: N Engl J Med Date: 2003-02-27 Impact factor: 91.245
Authors: Julian R Sampson; Sunil Dolwani; Sian Jones; Diana Eccles; Anthony Ellis; D Gareth Evans; Ian Frayling; Sheila Jordan; Eamonn R Maher; Tony Mak; Julie Maynard; Francesca Pigatto; Joan Shaw; Jeremy P Cheadle Journal: Lancet Date: 2003-07-05 Impact factor: 79.321
Authors: Christina Fleischmann; Julian Peto; Jeremy Cheadle; Bindiya Shah; Julian Sampson; Richard S Houlston Journal: Int J Cancer Date: 2004-04-20 Impact factor: 7.396
Authors: Siân Jones; Paul Emmerson; Julie Maynard; Jacqueline M Best; Sheila Jordan; Geraint T Williams; Julian R Sampson; Jeremy P Cheadle Journal: Hum Mol Genet Date: 2002-11-01 Impact factor: 6.150
Authors: Daniel Herzig; Karin Hardiman; Martin Weiser; Nancy You; Ian Paquette; Daniel L Feingold; Scott R Steele Journal: Dis Colon Rectum Date: 2017-09 Impact factor: 4.585
Authors: Alan H Tieu; Daniel Edelstein; Jennifer Axilbund; Katharine E Romans; Lodewijk A Brosens; Elizabeth Wiley; Linda Hylind; Francis M Giardiello Journal: J Clin Gastroenterol Date: 2016-08 Impact factor: 3.062
Authors: Elena M Stoffel; Erika Koeppe; Jessica Everett; Peter Ulintz; Mark Kiel; Jenae Osborne; Linford Williams; Kristen Hanson; Stephen B Gruber; Laura S Rozek Journal: Gastroenterology Date: 2017-11-14 Impact factor: 22.682